{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T06:20:37Z","timestamp":1790230837514,"version":"4.1.0"},"reference-count":51,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1016\/j.ejpb.2018.01.018","type":"journal-article","created":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T10:37:57Z","timestamp":1517481477000},"page":"19-28","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":60,"special_numbering":"C","title":["A new soluble and bioactive polymorph of praziquantel"],"prefix":"10.1016","volume":"127","author":[{"given":"Debora","family":"Zanolla","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5766-4014","authenticated-orcid":false,"given":"Beatrice","family":"Perissutti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadia","family":"Passerini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele R.","family":"Chierotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dritan","family":"Hasa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3830-8038","authenticated-orcid":false,"given":"Dario","family":"Voinovich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lara","family":"Gigli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Demitri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8734-6009","authenticated-orcid":false,"given":"Silvano","family":"Geremia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Keiser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Cerreia Vioglio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatrice","family":"Albertini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.ejpb.2018.01.018_b0005","doi-asserted-by":"crossref","first-page":"e464","DOI":"10.1371\/journal.pntd.0000464","article-title":"A novel biological activity of praziquantel requiring voltage-operated Ca2+ channel b subunits: subversion of flatworm regenerative polarity","volume":"3","author":"Nogi","year":"2009","journal-title":"PLoS Negl. Trop. Dis."},{"key":"10.1016\/j.ejpb.2018.01.018_b0010","unstructured":"WHO model list of essential medicines, 19 ed. (April 2015-Revised June 2015) Available at <http:\/\/www.who.int\/selection_medicines\/committees\/expert\/20\/EML_2015_FINAL_amended_JUN2015.pdf?ua=1> via the internet. WHO model list of essential medicines for children, 19 ed. (April 2015 - Revised June 2015) Available at: <http:\/\/www.who.int\/selection_medicines\/committees\/expert\/20\/EMLc_2015_FINAL_amended_JUN2015.pdf?ua=1 via the internet>."},{"issue":"2","key":"10.1016\/j.ejpb.2018.01.018_b0015","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.ejpb.2004.03.001","article-title":"Classification of orally administered drugs on the World Health Organization Model list of essential medicines according to the biopharmaceutics classification system","volume":"58","author":"Lindenberg","year":"2004","journal-title":"Eur. J. Pharm. Biopharm."},{"issue":"5","key":"10.1016\/j.ejpb.2018.01.018_b0020","doi-asserted-by":"crossref","first-page":"487","DOI":"10.2133\/dmpk.DMPK-10-RG-041","article-title":"Metabolite profiling of praziquantel and its analogs during the analysis of in vitro metabolic stability using information-dependent acquisition on a hybrid triple quadrupole linear ion trap mass spectrometer","volume":"25","author":"Huang","year":"2010","journal-title":"Drug Metab. Pharmacokinet."},{"issue":"4","key":"10.1016\/j.ejpb.2018.01.018_b0025","doi-asserted-by":"crossref","first-page":"546","DOI":"10.4269\/ajtmh.1998.59.546","article-title":"A mass chemotherapy trial of praziquantel on Schistosoma haematobium endemicity in Upper Egypt","volume":"59","author":"Talaat","year":"1998","journal-title":"Am. J. Trop. Med. Hyg"},{"issue":"11","key":"10.1016\/j.ejpb.2018.01.018_b0030","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1248\/cpb.47.1629","article-title":"Preparation, dissolution and characterization of praziquantel solid dispersions","volume":"47","author":"de La Torre","year":"1999","journal-title":"Chem. Pharm. Bull."},{"issue":"2","key":"10.1016\/j.ejpb.2018.01.018_b0035","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S0031-6865(97)00051-4","article-title":"Dissolution properties of praziquantel\u2013PVP systems","volume":"73","author":"El-Arini","year":"1998","journal-title":"Pharm. Acta Helv."},{"issue":"2","key":"10.1016\/j.ejpb.2018.01.018_b0040","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/j.ijpharm.2016.08.009","article-title":"Unexpected solvent impact in the crystallinity of praziquantel\/poly(vinylpyrrolidone) formulations. A solubility, DSC and solid-state NMR study","volume":"511","author":"Costa","year":"2016","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2018.01.018_b0045","first-page":"163","article-title":"Development and evaluation of praziquantel solid dispersions in sodium starch glycolate","volume":"12","author":"Chaud","year":"2013","journal-title":"Trop. J. Pharm. Res."},{"key":"10.1016\/j.ejpb.2018.01.018_b0050","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S0378-5173(98)00382-2","article-title":"Improvement of the in vitro dissolution of praziquantel by complexation with \u03b1-, \u03b2- and \u03b3-cyclodextrins","volume":"179","author":"Becket","year":"1999","journal-title":"Int. J. Pharm."},{"issue":"4","key":"10.1016\/j.ejpb.2018.01.018_b0055","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1208\/s12249-009-9346-7","article-title":"Effect of cyclodextrin complexation on the aqueous solubility and solubility\/dose ratio of praziquantel","volume":"10","author":"Maragos","year":"2009","journal-title":"AAPS PharmSciTech"},{"issue":"2","key":"10.1016\/j.ejpb.2018.01.018_b0060","first-page":"86","article-title":"Enhancement the oral bioavailability of praziquantel by incorporation into solid lipid nanoparticles","volume":"64","author":"Yang","year":"2009","journal-title":"Pharmazie"},{"issue":"2","key":"10.1016\/j.ejpb.2018.01.018_b0065","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.ijpharm.2017.05.053","article-title":"An explorative analysis of process and variables affecting comilling in a vibrational mill: the case of Praziquantel","volume":"533","author":"Perissutti","year":"2017","journal-title":"Int. J. Pharm."},{"issue":"1","key":"10.1016\/j.ejpb.2018.01.018_b0070","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.ijpharm.2015.09.019","article-title":"Development of flexible and dispersible oral formulations containing praziquantel for potential schistosomiasis treatment of pre-school age children","volume":"495","author":"Trastullo","year":"2015","journal-title":"Int. J. Pharm."},{"issue":"1\u20132","key":"10.1016\/j.ejpb.2018.01.018_b0075","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.ijpharm.2006.03.028","article-title":"Evaluation of melt granulation and ultrasonic spray congealing as techniques to enhance the dissolution of praziquantel","volume":"318","author":"Passerini","year":"2006","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2018.01.018_b0080","series-title":"Polymorphism in Molecular Crystals. Polymorphism in Molecular Crystals","author":"Bernstein","year":"2002"},{"key":"10.1016\/j.ejpb.2018.01.018_b0085","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0040-6031(94)01953-E","article-title":"Thermal analysis and calorimetric methods in the characterisation of polymorphs and solvates","volume":"248","author":"Giron","year":"1995","journal-title":"Thermochim. Acta"},{"key":"10.1016\/j.ejpb.2018.01.018_b0090","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1023\/A:1011052932607","article-title":"Ritonavir: an extraordinary example of conformational polymorphism","volume":"18","author":"Bauer","year":"2001","journal-title":"J. Pharm. Res."},{"key":"10.1016\/j.ejpb.2018.01.018_b0095","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1021\/cg301314w","article-title":"Cocrystals of active pharmaceutical ingredients praziquantel in combination with oxalic, malonic, succinic, maleic, fumaric, glutaric, adipic and pimelic acids","volume":"13","author":"Espinosa-Lara","year":"2013","journal-title":"Cryst. Growth Des."},{"issue":"1","key":"10.1016\/j.ejpb.2018.01.018_b0100","doi-asserted-by":"crossref","first-page":"e357","DOI":"10.1371\/journal.pntd.0000357","article-title":"A New incentive to switch to (R)-praziquantel in schistosomiasis treatment","volume":"3","author":"Meyer","year":"2009","journal-title":"PLoS Negl. Trop. Dis."},{"key":"10.1016\/j.ejpb.2018.01.018_b0105","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.ejps.2016.04.023","article-title":"Molecular and crystal structure of praziquantel. Spectroscopic properties and crystal polymorphism","volume":"92","author":"Borrego-S\u00e1nchez","year":"2016","journal-title":"Eur. J. Pharm. Sci."},{"issue":"1","key":"10.1016\/j.ejpb.2018.01.018_b0110","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1021\/acs.cgd.5b01254","article-title":"Chiral resolution of RS-praziquantel via diastereomeric Co-Crystal pair formation with malic acid","volume":"16","author":"Sanchez-Guadarrama","year":"2015","journal-title":"Cryst. Growth Des."},{"key":"10.1016\/j.ejpb.2018.01.018_b0115","unstructured":"R. Toro, J. Kaduk, M. Delgado, G. D\u00edaz de Delgado, Structural characterization of praziquantel: a broad spectrum anthelmintic, in powder diffraction. Powder Diffr. 2014, in: Proceedings of the International Centre for Diffraction Data (ICDD) Annual Spring Meetings, vol. 29, issue no 2, 2014, pp. 206\u2013207."},{"key":"10.1016\/j.ejpb.2018.01.018_b0120","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.jchromb.2012.05.004","article-title":"Simple, cheap and effective high-performance liquid chromatographic method for determination of praziquantel in bovine muscle","volume":"899","author":"Sun","year":"2012","journal-title":"J. Chromatogr. B"},{"issue":"2","key":"10.1016\/j.ejpb.2018.01.018_b0125","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.tetasy.2013.11.004","article-title":"A straightforward and efficient synthesis of praziquantel enantiomers and their 40-hydroxy derivatives","volume":"25","author":"Cedillo-Cruz","year":"2014","journal-title":"Tetrahedr.: Asymm."},{"issue":"9","key":"10.1016\/j.ejpb.2018.01.018_b0130","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1016\/j.tetasy.2006.04.023","article-title":"Enantioselective synthesis of (R)-(\u2212)-praziquantel (PZQ)","volume":"17","author":"Roszkowski","year":"2006","journal-title":"Tetrahed.: Asymm."},{"issue":"3","key":"10.1016\/j.ejpb.2018.01.018_b0135","first-page":"1","article-title":"Status of the crystallography beamlines at Elettra","volume":"130","author":"Lausi","year":"2015","journal-title":"EPJ Plus"},{"key":"10.1016\/j.ejpb.2018.01.018_b0140","doi-asserted-by":"crossref","unstructured":"A.P. Hammersley, S.O. Svensson, M. Hanfland, A.N. Fitch, D. H\u00e4usermann, Two-q dimensional detector software: from real detector to idealised image or two-theta scan. High Press. Res. 14 (1996) 235\u2013248. Hammersley, A. P. ESRF Internal Report 1998, ESRF98HA01T, FIT2D V9.129 Reference Manual V3.1.","DOI":"10.1080\/08957959608201408"},{"key":"10.1016\/j.ejpb.2018.01.018_b0145","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1524\/zkri.220.5.567.65075","article-title":"First principles methods using CASTEP","volume":"220","author":"Clark","year":"2005","journal-title":"Z. Kristallogr. \u2013 Cryst. Mater."},{"key":"10.1016\/j.ejpb.2018.01.018_b0150","doi-asserted-by":"crossref","first-page":"20130270","DOI":"10.1098\/rsta.2013.0270","article-title":"Density functional theory in the solid state","volume":"372","author":"Hasnip","year":"2014","journal-title":"Philos. Trans. R. Soc. A-Math. Phys. Eng. Sci."},{"key":"10.1016\/j.ejpb.2018.01.018_b0155","doi-asserted-by":"crossref","first-page":"245101","DOI":"10.1103\/PhysRevB.63.245101","article-title":"All-electron magnetic response with pseudopotentials: NMR chemical shifts","volume":"63","author":"Pickard","year":"2001","journal-title":"Phys. Rev. B."},{"key":"10.1016\/j.ejpb.2018.01.018_b0160","doi-asserted-by":"crossref","first-page":"3865","DOI":"10.1103\/PhysRevLett.77.3865","article-title":"Generalized gradient approximation made simple","volume":"77","author":"Perdew","year":"1996","journal-title":"Phys. Rev. Lett."},{"key":"10.1016\/j.ejpb.2018.01.018_b0165","doi-asserted-by":"crossref","first-page":"205414","DOI":"10.1103\/PhysRevB.80.205414","article-title":"Azobenzene at coinage metal surfaces: role of dispersive van der Waals interactions","volume":"80","author":"McNellis","year":"2009","journal-title":"Phys. Rev. B."},{"key":"10.1016\/j.ejpb.2018.01.018_b0170","doi-asserted-by":"crossref","first-page":"73005","DOI":"10.1103\/PhysRevLett.102.073005","article-title":"Accurate molecular Van Der Waals interactions from ground-state electron density and free-atom reference data","volume":"102","author":"Tkatchenko","year":"2009","journal-title":"Phys. Rev. Lett."},{"issue":"4","key":"10.1016\/j.ejpb.2018.01.018_b0175","first-page":"157","article-title":"Photothermal stability of praziquantel","volume":"12","author":"Suleiman","year":"2004","journal-title":"Saudi Pharmaceut. J."},{"issue":"9","key":"10.1016\/j.ejpb.2018.01.018_b0180","doi-asserted-by":"crossref","first-page":"5466","DOI":"10.1128\/AAC.02741-14","article-title":"Activity of praziquantel enantiomers and main metabolites against schistosoma mansoni","volume":"58","author":"Meister","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"issue":"4","key":"10.1016\/j.ejpb.2018.01.018_b0185","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1128\/AAC.01537-06","article-title":"In vitro and in vivo activities of synthetic trioxolanes against major human schistosome species","volume":"51","author":"Xiao","year":"2007","journal-title":"Antimicrob. Agents Chemother."},{"issue":"12","key":"10.1016\/j.ejpb.2018.01.018_b0190","doi-asserted-by":"crossref","first-page":"3039","DOI":"10.1002\/jps.20211","article-title":"Structural characterization and enantioseparation of the chiral compound praziquantel","volume":"93","author":"Liu","year":"2004","journal-title":"J. Pharm. Sci."},{"issue":"4","key":"10.1016\/j.ejpb.2018.01.018_b0195","doi-asserted-by":"crossref","first-page":"557","DOI":"10.3109\/10837459809028638","article-title":"Solubility properties of racemic Praziquantel and its enantiomers","volume":"3","author":"El-Arini","year":"1998","journal-title":"Pharm. Dev. Technol."},{"key":"10.1016\/j.ejpb.2018.01.018_b0200","series-title":"Analytical Profile of Drug Substances and Excipients","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/S0099-5428(08)60760-1","article-title":"Praziquantel","author":"El-Subbagh","year":"1998"},{"key":"10.1016\/j.ejpb.2018.01.018_b0205","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1107\/S0021889813013113","article-title":"EXPO2014","volume":"46","author":"Altomare","year":"2013","journal-title":"J. Appl. Cryst."},{"key":"10.1016\/j.ejpb.2018.01.018_b0210","unstructured":"A.A. Coelho, TOPAS-Academic, version 4.1, Coelho Software, Brisbane, Australia, 2007."},{"key":"10.1016\/j.ejpb.2018.01.018_b0215","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1002\/chir.20251","article-title":"Investigation of the phase diagrams of chiral praziquantel","volume":"18","author":"Liu","year":"2006","journal-title":"Chirality"},{"issue":"2","key":"10.1016\/j.ejpb.2018.01.018_b0220","first-page":"148","article-title":"Structure validation in chemical crystallography","volume":"D65","author":"Spek","year":"2009","journal-title":"Acta Cryst."},{"key":"10.1016\/j.ejpb.2018.01.018_b0225","doi-asserted-by":"crossref","first-page":"5897","DOI":"10.1039\/C4CE00367E","article-title":"Polymorphs and co-crystals of haloprogin: an antifungal agent","volume":"16","author":"Baldrighi","year":"2014","journal-title":"CrystEngComm"},{"key":"10.1016\/j.ejpb.2018.01.018_b0230","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1211\/jpp.59.2.0009","article-title":"Applications of solid-state NMR to pharmaceutical polymorphism and related matters","volume":"59","author":"Harris","year":"2007","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.ejpb.2018.01.018_b0235","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1002\/chem.200600760","article-title":"Polymorphism in crystalline cinchomeronic acid","volume":"13","author":"Braga","year":"2007","journal-title":"Chem.-Eur. J."},{"key":"10.1016\/j.ejpb.2018.01.018_b0240","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.dyepig.2016.03.035","article-title":"Crystal structure and tautomerism of Pigment Yellow 138 determined by X-ray powder diffraction and solid-state NMR","volume":"131","author":"Gumbert","year":"2016","journal-title":"Dyes Pigments"},{"key":"10.1016\/j.ejpb.2018.01.018_b0245","doi-asserted-by":"crossref","first-page":"2564","DOI":"10.1021\/ja909449k","article-title":"Powder crystallography by combined crystal structure prediction and high-resolution 1H solid-state NMR spectroscopy","volume":"132","author":"Salager","year":"2010","journal-title":"J. Am. Chem. Soc."},{"issue":"4","key":"10.1016\/j.ejpb.2018.01.018_b0250","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1007\/s00894-017-3266-3","article-title":"Molecular Modeling and Infrared and Raman spectroscopy of the crystal structure of the antiparasitic drug Praziquantel","volume":"23","author":"Borrego-S\u00e1nchez","year":"2017","journal-title":"J. Mol. Model."},{"issue":"1","key":"10.1016\/j.ejpb.2018.01.018_b0255","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.ejps.2013.03.018","article-title":"Reduction of melting temperature and enthalpy of drug crystals: theoretical aspects","volume":"50","author":"Hasa","year":"2013","journal-title":"Eur. J. Pharm. Sci."}],"container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641117309323?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641117309323?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,10,10]],"date-time":"2019-10-10T00:21:09Z","timestamp":1570666869000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0939641117309323"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6]]},"references-count":51,"alternative-id":["S0939641117309323"],"URL":"https:\/\/doi.org\/10.1016\/j.ejpb.2018.01.018","relation":{},"ISSN":["0939-6411"],"issn-type":[{"value":"0939-6411","type":"print"}],"subject":[],"published":{"date-parts":[[2018,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A new soluble and bioactive polymorph of praziquantel","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutics and Biopharmaceutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejpb.2018.01.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}